The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of acoramidis in the EU based on ...

Bayer AG won the backing of European Union regulators for its cardiology drug as the German company fights to offset the ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...

The findings could potentially enable patients to be identified and treated before symptoms of ATTR-CM emerge.

BridgeBio Pharma (BBIO) announced the Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion ...

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-four brokerages that are covering the firm, Marketbeat ...

The European Medicines Agency’s (EMA) human medicines committee (CHMP) recommended another batch medicines for approval at ...

BridgeBio Pharma (BBIO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorization in the European Union for acoramidis for ...

The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 ...

The U.S. Food and Drug Administration has approved a drug developed at Stanford Medicine that offers hope to people diagnosed ...

The office of Senate Majority Leader Chuck Schumer (D-N.Y.) said that this week he will bring the HEARTS Act, the bipartisan ...

The new understanding of molecular events that drive the various forms of amyloidosis has generated treatment strategies that ...